OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe
By: OncoBeta GmbH
The jury consisting of CEOs, CIOs, VCs, industry analysts and MedTech Outlook´s editorial board members selected OncoBeta GmbH and its Rhenium-SCT®
„Being one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer, it is our goal to provide patients and healthcare professionals with the most efficient and innovative therapies possible," states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH.
View the Top 20 MedTech Solution Providers in Europe under the Digital Magazine Link at:
Read the Interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH directly at:
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT®
About the Rhenium-SCT®
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT®
Find out more about the Rhenium-SCT®
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
85748 Garching bei München